<DOC>
	<DOCNO>NCT01657799</DOCNO>
	<brief_summary>The primary objective study evaluate Overall Survival , Best Tumor Response Rate , Time Intracranial Progression ( radiographic ) , Time Clinical Brain Metastasis Progression , safety , tolerability veliparib Whole Brain Radiation Therapy subject brain metastasis Non Small Cell Lung Cancer</brief_summary>
	<brief_title>A Clinical Study Conducted Multiple Centers Comparing Veliparib Whole Brain Radiation Therapy ( WBRT ) Versus Placebo WBRT Subjects With Brain Metastases From Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Subject must great equal 18 year age Subject must cytologically histologically confirm nonsmall cell lung cancer Subject must brain metastasis demonstrate MRI brain scan Subject must eligible WBRT Subject diagnose brain metastasis great 28 day prior treatment Subject receive prior form cranial radiation and/or neurosurgery brain metastasis Subject 's last dose anticancer therapy investigational therapy less equal 7 day prior treatment Subject Karnofsky Performance Score less 70 Subject significant dyspnea require supplemental oxygen therapy Subject liver metastasis ( restaging require know liver metastasis ) Subject 2 site ( organ system ) metastases nonsmall cell lung cancer exception intracranial site metastases nonsmall cell lung cancer , thoracic site metastases nonsmall cell lung cancer bone metastases Subject leptomeningeal metastasis subarachnoid spread tumor Subject unresolved unstable , serious toxicity prior administration another investigational drug and/or prior anticancer treatment Subject know seizure disorder uncontrolled , seizure occur great equal 3 time week past month . Subjects present symptom seizure brain metastasis eligible ; however he/she receive adequate antiseizure medication prior study treatment Subject pregnant lactating Subject previously treat poly ( ADPribose ) polymerase inhibitor investigational agent Subject clinically significant uncontrolled major medical condition ( ) Subject history another active cancer within past 5 year except : cervical cancer situ , situ carcinoma bladder , basal squamous cell carcinoma skin cancer situ consider cure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>